BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope ...

“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.

The intranasal delivery method of Naloxone presents several benefits, such as ease of use and the elimination of the need for medical professionals during administration, making it more accessible ...

Theglobal marketfor Naloxone is rapidly growing, with intranasal delivery offering significant advantages such as ease of use and greater accessibility for emergency response. Polyrizon is ...

This collaboration aims to utilize Polyrizon's proprietary intranasal hydrogel technology to improve the delivery and effectiveness of psychedelic treatments, highlighting the potential of ...

Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...

This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy ...

This agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential ...